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a b s t r a c t
Progressive multifocal leukoencephalopathy (PML) is a disease of immunocompromised
patients caused by reactivation of the John Cunningham polyomavirus (JCV).
A monoclonal anti-CD20 antibody rituximab is widely used as an important part of
therapy for B-cell non-Hodgkin lymphomas and various autoimmune diseases. It is not
fully explained how rituximab reactivates JCV.
In this report, we present the case of a 61-year-old man with T-cell/histiocyte-rich
large B-cell lymphoma who was treated with R-CHOP and intrathecal methotrexate. Two
weeks after the first R-CHOP course he developed dysarthria, diplopia, and disturbances
in motor coordination. Based on CT/MRI results showing 3 cm  2 cm large hypodense
white matter lesion in left cerebellar hemisphere, and detection of JCV in the cerebros-
pinal fluid (14 300 viral copies/mL), the patient was diagnosed with PML. Despite treat-
ment attempt with cidofovir and IVIG, the patient’s neurological status continued to
worsen. He developed progressive motor neuron deficits but retained intact cognitive
functions. The patient deceased nearly three months after onset of rituximab treatment.
Rituximab is a milestone in treatment of many hematological and autoimmune disea-
ses. Considering how widespread has the use of rituximab become, the overall risk of
developing PML is relatively low. Nevertheless, since the end of 1990s several reports
were published on PML development in association with usage of rituximab. The authors
would like to emphasize that although the total risk of PML occurrence in patients trea-
ted with rituximab is low, it is important that physicians administrating rituximab the-
rapy are aware of this serious complication.
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Progressive multifocal leukoencephalopathy (PML) is a rare,
albeit often fatal, central nervous system (CNS) demyelinat-
ing disorder caused by reactivation of a latent John Cun-
ningham polyomavirus (JCV) [1–3]. The disease was first
described in 1950s by a Swedish neuropathologist Karl-Erik
Åström as a complication occurring in patients with chronic
lymphocytic leukemia (CLL) and Hodgkin lymphoma [1].
Primary JCV infection is usually asymptomatic and occurs
in school age. After that, the virus is latent in 70–90% of the
adult population [2]. Latent JCV can be found in kidney
epithelial cells, CD34+ hematopoietic cells and possibly
early B-cell precursors [4]. It was proposed that hemato-
poietic stem cells, which carry JCV, can act as Trojan horses
and thus enable the virus to pass the blood-brain barrier.
During the active phase of the PML, JCV particles are
replicated in oligodendrocytes. The virus induces then
destruction of myelin sheath and cell death [2].
PML is usually associated with a decreased T-cell
response, and it was very infrequent disease until the time
of HIV-epidemics in the 1980s [5]. The incidence of PML
increased 50 times between 1979 and 1994, but then it has
decreased gradually due to the introduction of antiviral
treatment of HIV infection.
The rate of PML progression may initially be slow, making
the disease difficult to diagnose. Patients present gradual
worsening of cognitive functions, speech and vision [1, 2].
Symptoms become more prominent with time, and patients
develop motor neuron deficits and ataxia. With disease
progression, neurologic deficits accelerate with occurrence of
dementia, blindness, pareses, followed by coma and
decease. PML diagnosis is confirmed by JCV detection by
polymerase chain reaction (PCR) in cerebrospinal fluid (CSF)
[2]. Magnetic resonance imaging (MRI) demonstrates typical
pictures of multifocal asymmetrical white matter lesions,
located in cerebral hemispheres and less often in cerebellum
or brain stem. Diagnosis can also be obtained through
biopsy, with histopathological analysis of the tissue and
complementary immunohistochemical stains (Table I) [2, 6].
Rituximab is a monoclonal anti-CD20 antibody used for
treatment of many types of CD20-positive non-Hodgkin
lymphomas (NHLs) including CLL [2]. It is also successfully
used in autoimmune diseases, including rheumatoid arthri-
tis (RA) and systemic lupus erythematosus (SLE). Expression
of CD20 antigen is observed on both healthy and malignantTable I – Diagnostic signs and symptoms of progressive multi
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Radiological findings MRI or CT
only discrB-cells, but not on hematopoietic stem cells. Rituximab
produces a rapid and almost complete clearance of B-cells
from peripheral blood, with the effect persisting up to 12
months after completed therapy [7].
Case presentation
A 61-year-old previously healthy Swedish man with
a periodical alcohol abuse, presented with a three-months-
long history of diffuse abdominal pain, tiredness and weight
loss. Computed tomography (CT) imaging revealed abdom-
inal and thoracic lymphadenopathy at multiple sites as well
as prominent splenomegaly. Lymph node biopsy disclosed
infiltration of T-cell/histiocyte-rich large B-cell lymphoma.
The patient was scheduled for 6 courses of R-CHOP (ritux-
imab, cyclophosphamide, doxorubicin, vincristine, predniso-
lone) at 14-day intervals and intrathecal methotrexate. He
was also found to have undergone hepatitis B, and treat-
ment with lamivudin (ZeffixTM) was initiated.
Two weeks after the first R-CHOP-14 course the patient
came for a follow-up visit and evaluation before the next
treatment course. He presented dysarthria and reported
experiencing diplopia, disturbances in motor coordination
and loss of large muscle group strength for several days
before. Lymphoma therapy was postponed and the patient
was admitted to the department of neurology. Brain CT was
performed on the same day, and revealed the presence of
3 cm  2 cm large hypodense white matter lesion in left
cerebellar hemisphere as well as numerous nonspecific
white matter lesions. These findings were later confirmed
by MRI and tentative radiological diagnosis was lymphoma
or PML or low grade tumor. Lumbar puncture was per-
formed, with extensive examination for potential infectious
agents. The initial assessment suggested CNS involvement
by lymphoma since only one major lesion was detected and
its location was atypical for PML.
Results of JCV-PCR analysis in the CSF sample were
received 3 weeks after initiation of the first R-CHOP-14 course,
demonstrating 14 300 viral copies/mL (Fig. 1). Other assays
failed to reveal any bacteria, virus or fungal infection. A brain
biopsy was discussed with neurosurgeons, but they advised
against biopsy as clear signs of PML were already identified.
The patient’s clinical status has gradually improved,
and 4 weeks after R-CHOP treatment onset he was in
neurologically nearly normal condition apart from minor
problems with his body balance. At that time, the number offocal leukoencephalopathy
ogressing neurological deficits and worsening of motor neuron
 usually cognitive defect and impaired field of vision
istic histopathological findings [7]:
nisation
strocytes
 oligodendroglial cell nuclei
onstrated by immunohistochemical stain or in electron microscopy
 of JCV in CSF by means of PCR








0 1 2 3 4 5 6 7 8
Number of JCV copies/mL
Weeks aer onset of R-CHOP
Fig. 1 – Changes in patient’s JCV levels in cerebrospinal fluid samples over time
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New brain MRI scans taken on the same day revealed though
a new band-like lesion with contrast enhancement in proxi-
mity to the already known lesion in the left cerebellum
hemisphere.
Four weeks after onset of the first R-CHOP course the
patient received another one, but this time only CHOP
without rituximab due to suspected PML. No intrathecal
methotrexate was given. He was discharged home, with
planned follow-up visit at the outpatient clinic two weeks
later. However, he did not show up to the appointment,
and did not answer phone calls.
A couple of days later he presented to the emergency
department with newly appearing neurological symptoms
and inability to walk. Clinical examination revealed dysar-
thria, decreased strength in large muscle groups and
decreased fine motor neuron function on the left side, with
positive Babinski sign on the left, involuntary movements
and inability to stand still.
Acute MRI of the brain was ordered, with suspicion of
rapid PML progression. That was confirmed on MRI scans,
with new lesions appearing in the upper part of medulla
oblongata and pons. The previously described big lesion in
cerebellum has further increased in size, with apparent
cystic degeneration and necrosis. New lesions appeared in
the right parietal lobe. Multiple plaque-like white matter
lesions were still visible. Contrast enhancement was very
discrete, a feature characteristic for the PML (Fig. 2). Radi-
ological and clinical findings pointed clearly to PML, with
progression since the first diagnosis.
The patient has received cidofovir (5 mg/kg i.v.) twice, as
well as two doses of intravenous immunoglobulin (IVIG). At
the time of hospital admission number of JCV copies in CSF
increased to 22 200 copies/mL (i.e., approx. 7 weeks after
initiation of R-CHOP therapy) (Fig. 1). CT scans of thoraxand abdomen revealed slight reduction in size of the
enlarged lymph nodes as compared to the status before the
first R-CHOP course. Fearing that PML can further progress,
a decision was made to abstain from intensive immuno-
chemotherapy, and the patient was given a single dose
intravenous vincristine (OncovinTM).
Unfortunately, the patient’s clinical condition continued
to worsen. He developed progressive motor neuron deficits
but retained intact cognitive functions. The patient demon-
strated difficulties in swallowing, was unable to speak, and
experienced significant problems due to mucus accumula-
tion in the respiratory tract in course of an infection for
which he was given broad spectrum antibiotics. A total
parenteral nutrition was started as he could not swallow
without the risk of aspiration into airways.
Three months after the first R-CHOP course the discus-
sion was commenced on the possibility of therapy with T-
cells specific against JCV and patient’s siblings were HLA-
typed. Moreover, experimental usage of interleukin 7 (IL-7)
in patient was discussed. However, this was considered as
pointless as the patient’s lymphoma was not in remission,
and more intensive treatment would be required which
would further aggravate the patient’s PML. JCV specific T-
cell therapy was also abandoned as the patient’s status was
deemed not compatible with the study prerequisites, which
among others included performing a positron emission
tomography before infusion of T-cells. The patient’s neuro-
logical status continued to worsen, and he deceased
nearly three months after the administration of rituximab
treatment.
During the course of patient’s care, a report was sent to
the Swedish Medical Products Agency (Läkemedelsverket)
concerning PML as a suspected adverse event of therapy
with MabTheraTM (rituximab), and a notice was sent to the
drug producer, a pharmaceutical company F. Hoffman-La
Fig. 2 – MRI scans of patient’s brain with widespread PML lesions in left cerebellar hemisphere, medulla oblongata, and pons
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implied between usage of the medical agent MabTheraTM
and the adverse event of PML occurrence. The Agency
pointed out that cyclophosphamide, doxorubicin and vin-
cristine should also be perceived as other potential causa-
tive agents.
Discussion
Monoclonal antibodies have revolutionized treatment of
multiple hematological and autoimmune diseases and are
currently in widespread use. In Sweden, with a population
of approx. 10 million people, almost 2000 new cases of
malignant lymphoma are diagnosed each year in adults,
most of these representing B-cell NHL with CD20-positivity.
Of those, the most common diagnoses include diffuse large
B-cell lymphoma, follicular lymphoma and CLL, which
constitute two-thirds of all newly diagnosed lymphomas.
PML as a complication of rituximab therapy was first
noted in the end of 1990s [2]. Between 1997 and 2008 only, 57
cases of rituximab-associated PML were reported worldwide,
including 52 patients with B-cell NHL, 2 patients with SLE,
one patient with RA, one patient with idiopathic autoim-
mune pancytopenia, and one patient with idiopathic throm-bocytopenic purpura (ITP) [8]. To the best of our knowledge,
only one case of rituximab-associated PML in NHL was
reported up till now in Sweden [9]. The case concerned
a female patient with a transformed high-grade B-cell NHL.
However, we were not able to identify any Swedish
report on rituximab-associated PML in patient with newly
diagnosed B-NHL who developed PML after just a single
course of rituximab. It is very unusual with such short time
between administration of rituximab and the onset of PML,
but based on our case, apparently possible. According to
the study by Carson et al., median time from the first
rituximab dose to diagnosis of PML was 16 months (range
1–90 months) [8]. Noteworthy, median time between the
last dose of rituximab and symptomatic JCV viral reactiva-
tion was 5.5 months. On average, six doses of rituximab
(range 1–28 doses) were administered before PML diagnosis
was made, and a median survival time following PML
diagnosis was 2 months (range 0.4–122 months) [8].
Possible factors predisposing to a more rapid PML
progression include lower CD4+ count (<200 cells/mL; ref.:
500–1600) and onset of PML signs shortly after the last
administered rituximab dose (within 3 months) [8, 10]. All
the patients who developed PML within 3 months from
rituximab infusion died, as compared to 84% patients who
developed PML more than 3 months after the last obtained
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was not assessed. However, the correlation between
a development of PML soon after rituximab infusion and
a rapid progression of the disease could be observed.
Currently, there is no effective treatment of PML avail-
able [11]. Cytarabine has been tried in most cases but
studies on HIV-positive patients with PML did not reveal
any beneficial effect of neither intravenous or intrathecal
cytarabine on survival [12, 13]. However, several reports
demonstrated a certain improvement of PML in HIV-nega-
tive patients following intrathecal administration of cytar-
abine [14]. Other reported treatment attempts included
administration of mirtazapine, cidofovir, donor lymphocyte
infusion (DLI), IVIG and risperidone [2]. The presented
patient unfortunately did not experience any beneficial
effect of cidofovir or IVIG.
Mortality in rituximab-associated PML in patients treated
for NHL is very high [2, 11, 15]. In the previously mentioned
study, Carson et al. reported that 90% patients died due to
PML, and all the survivors had persistent neurological
symptoms [8]. A slightly better survival was observed in
patients who developed PML after stem cell transplantation,
either autologous or allogeneic [8, 16]. One can speculate that
it may be due to the fact that the transplanted patient has
a better ability to recover immune system in the long run.
Rituximab as a trigger of PML
Pathophysiological mechanism behind correlation of ritux-
imab treatment and PML is not well understood. One theory
suggests that depletion of mature B-cells following rituximab
administration facilitates expansion of pre-B-cells infected
with JCV [2]. Studies have shown that B-cell reconstitution
after rituximab therapy causes a disproportional increase in
immature B-cells [7, 17] but the explanation to this phenom-
enon is probably more complex.
Patients with ITP who had been administered rituximab
had changes in T-cell activity following B-cell depletion [18].
A study done in patients with multiple sclerosis (MS)
showed decrease of the total T-cell count in CSF up to
6 months after rituximab administration [19]. Other studies
demonstrated however quite an opposite effect of rituximab
on T-cell population [20].
Bennett proposed a hypothesis on the role of bone
marrow in rituximab-associated PML [4]. His analysis of
bone marrow samples showed that all 5 specimens
obtained from patients with lymphoma and PML were
positive for JCV, compared to only 2 out of 86 bone marrow
samples from patients who had lymphoma but not PML.
Indeed, JCV remains in latent form in CD34+ hematopoietic
stem cells and most likely also in immature B-cells.
Chemotherapy mobilizes stem cells from bone marrow and
induces quantitative reduction in the T-cell population.
According to Bennett’s theory rituximab diminishes then
the qualitative T-cell response, and progenitor cells bearing
latent JCV proliferate following the overall B-cell depletion
[4]. However, the hypothesis was based on retrospective
findings, and was never laboratory verified.
Occurrence of PML was also observed in untreated
patients with lymphomas, it is therefore difficult to assesshow much does rituximab itself increase the risk of the
disease. An Italian study of 976 patients with NHL demon-
strated a significantly higher risk of developing PML in
subjects treated with rituximab [21]. It is currently difficult
to perform similar studies, as rituximab is a part of
standard therapy protocols in B-cell NHLs. Besides, PML
occurred after rituximab therapy even in patients not
having a lymphoma, e.g. in subjects with SLE or RA.
Another issue is the extent to which chemotherapy
included in lymphoma treating protocols contributes to
immunomodulation and PML development [11, 15]. Carson
et al. pointed out that all patients who developed PML had
previously received treatments affecting the immune sys-
tem, including alkylating agents, corticosteroids, purine
analogs or immunomodulators for prevention of graft-
versus-host disease (GvHD) after allogeneic stem cell trans-
plantation [8]. Some of these patients had though been
treated with rituximab and steroids but not cytotoxic drugs.
Rituximab seems therefore to induce PML even without the
context of chemotherapy.
The present patient had not been treated with che-
motherapy until administration of R-CHOP, but he had been
given high dose cortisone pretreatment for 3 weeks while
awaiting definitive histopathological confirmation of NHL.
In his case we could not identify an underlying defect in
cellular immunity. He developed neurological symptoms
already 10 days after receiving first R-CHOP cycle, which
points to an unusually rapid disease onset. He improved
spontaneously after the first PML symptoms and 14 days
later he was in an apparently normal clinical condition,
which is different from a known natural PML course. At
that time even the number of JCV copies decreased sponta-
neously in his CSF sample (Fig. 1).
The patient developed next episode of the disease
approx. 2–3 weeks following the second CHOP course (this
time without rituximab), and JCV titer in CSF was even
higher than during the first symptomatic episode. It is
unclear why he initially improved but it can be assumed
that CHOP treatment without rituximab contributed to PML
reactivation. It would be interesting to know if the patient
had low titers of CD4+ cells from the beginning, and, if so,
was the lymphoma that caused this phenomenon or was
there another causative factor. However, a routine infec-
tious work-up was performed at the time of NHL diagnosis,
and the patient was found to be HIV-negative.
Other agents that may cause PML
Development of PML can also be induced by monoclonal
antibodies other than rituximab [2, 22–25].
Natalizumab is an antibody binding alfa4-integrin on T-
cells and it is successfully used in therapy of refractory MS
[2, 22]. The first ever case of natalizumab-associated PML
was reported in 2005, and the agent was removed from the
market. Currently, natalizumab is again in use but only
under strict control for occurrence of any PML-symptoms [23,
24]. Mortality in natalizumab-induced PML is markedly lower
as compared to cases where rituximab was the trigger [2, 22].
One may speculate if it is because MS patients are in general
more immunocompetent than patients with lymphomas.
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treatment of plaque psoriasis. Several cases of efalizumab-
associated PML were reported and as a result the antibody was
retrieved from market in 2009 and is no longer in use [2, 23].
Other drugs that can possibly induce PML include potent
immunosuppressive agents such as tacrolimus or cyclos-
porine [25].
Conclusions
Rituximab is a milestone in treatment of many hematologi-
cal and autoimmune diseases. Nevertheless, since the end
of 1990s several reports were published on PML develop-
ment in association with usage of this antibody. Risk of
PML has increased with rituximab therapy but considering
how widespread has the use of rituximab become, the
overall risk of developing PML is relatively low [2, 8].
Further studies are warranted for a better understanding
of rituximab interaction with T-cells and its immunomodu-
latory mechanisms. Ideally, a strategy should be elaborated
to identify at an early stage patients at risk of developing
PML. Measuring the CD4+ cell count at initiation of ritux-
imab treatment can be of value. During ongoing rituximab
therapy a close clinical follow-up is crucial so as to detect
any developing neurological signs or symptoms which can
point to PML, and the disease should always be included in
differential diagnosis.
In the described case clinical suspicion of PML was made
early after symptoms onset, and because of this rituximab
was withdrawn from therapy protocol. This however did
not improve patient’s outcome, resulting in decease
3 months after PML symptom onset.
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